Abstract:Although current stem cell therapies exhibit promising potential, the extended process of employing autologous cells and the necessity for donor-host matching to avert the rejection of transplanted cells significantly limit the widespread applicability of these treatments. It would be highly advantageous to generate a pluripotent universal donor stem cell line that is immune-evasive and, therefore, not restricted by the individual's immune system, enabling unlimited application within cell replacement therapies. Before such immune-evasive stem cells can be moved forward to clinical trials, in vivo testing via transplantation experiments in immune-competent animals would be a favorable approach preceding preclinical testing. By using human stem cells in immune competent animals, results will be more translatable to a clinical setting, as no parts of the immune system have been altered, although in a xenogeneic setting. In this way, immune evasiveness, cell survival, and unwanted proliferative effects can be assessed before clinical trials in humans. The current study presents the generation and characterization of three human embryonic stem cell lines (hESCs) for xenogeneic transplantation in immune-competent mice. The major histocompatibility complexes I- and II-encoding genes, B2M and CIITA, have been deleted from the hESCs using CRISPR-Cas9-targeted gene replacement strategies and knockout. B2M was knocked out by the insertion of murine CD47. Human-secreted embryonic alkaline phosphatase (hSEAP) was inserted in a safe harbor site to track cells in vivo. The edited hESCs maintained their pluripotency, karyotypic normality, and stable expression of murine CD47 and hSEAP in vitro. In vivo transplantation of hESCs into immune-competent BALB/c mice was successfully monitored by measuring hSEAP in blood samples. Nevertheless, transplantation of immune-evasive hESCs resulted in complete rejection within 11 days, with clear immune infiltration of T-cells on day 8. Our results reveal that knockout of B2M and CIITA together with species-specific expression of CD47 are insufficient to prevent rejection in an immune-competent and xenogeneic context.

A Safety Checkpoint to Eliminate Cancer Risk of the Immune Evasive Cells Derived from Human Embryonic Stem Cells.

An Effective Approach to Prevent Immune Rejection of Human ESC-derived Allografts.

Protecting Against Wayward Human Induced Pluripotent Stem Cells with a Suicide Gene.

An Efficient Combination Immunotherapy for Antitumor Immunity Without Accelerating Cardiac Allograft Rejection.

A Scalable Approach to Prevent Teratoma Formation of Human Embryonic Stem Cells

Using Gene Editing to Establish a Safeguard System for Pluripotent Stem-Cell-Based Therapies.

Engineering human pluripotent stem cell lines to evade xenogeneic transplantation barriers

CRISPR-Cas9 immune-evasive hESCs are rejected following transplantation into immunocompetent mice

The Immunogenicity and Immune Tolerance of Pluripotent Stem Cell Derivatives

Developing enhanced immunotherapy using NKG2A knockout human pluripotent stem cell-derived NK cells

Safe Engineering of Cancer-Associated Fibroblasts Enhances Checkpoint Blockade Immunotherapy.

Suicide Gene-Mediated Ablation of Tumor-Initiating Mouse Pluripotent Stem Cells

Generating Hescs with Reduced Immunogenicity by Disrupting TAP1 or TAPBP

Safe scarless cassette-free selection of genome-edited human pluripotent stem cells using temporary drug resistance

Rerovirus Mediated Hsv-Tk Gene Transfer Can Influence The Function Of Human T-Lymphocyte

Generation of hypoimmunogenic human pluripotent stem cells via expression of membrane-bound and secreted β2m-HLA-G fusion proteins

Stem Cell Therapy and Immunological Rejection in Animal Models

Repair of Acute Liver Damage with Immune Evasive Hesc Derived Hepato-Blasts.

Development of an inducible caspase-9 safety switch for pluripotent stem cell–based therapies

Generating Hypoimmunogenic Human Embryonic Stem Cells by the Disruption of Beta 2-Microglobulin

Hesc-Derived Immune Suppressive Dendritic Cells Induce Immune Tolerance of Parental Hesc-Derived Allografts.